Answer
Glyxambi is contraindicated in people with hypersensitivity to empagliflozin or linagliptin, any other SGLT2 inhibitor, any other DPP-4 inhibitor, or any excipient listed in section 6.1.
Sources for this answer
- Glyxambi 10 mg/5 mg film-coated tablets and Glyxambi 25 mg/5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.3 Contraindications · Version 14Document updated
Sources checked